Gaucher disease
Drug research and approvals for gaucher disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 25 studies of gaucher disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, FDA has 6 approved and 17 open orphan designations naming it, and the EU has 7 authorised medicines for it.
- Recruiting worldwide: 25
- Trials authorized in Canada: 7
- FDA orphan approvals: 6
- EU medicines: 7
- Parkinson's Disease in Type 1 Gaucher DiseaseNCT07886879 · Not reported · Icahn School of Medicine at Mount Sinai · starts Sep 21, 2026
- Advancing Integrated Therapies for Gaucher DiseaseNCT07758816 · Not reported · Yale University · starts May 6, 2026
- A Gaucher Disease Gene Therapy Trial With FLT201NCT07223944 · Phase 3 · Spur Therapeutics · starts Apr 7, 2026
- A Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher DiseaseNCT06818838 · Phase 1 / Phase 2 · Lingyi Biotech Co., Ltd. · starts Jul 5, 2024
- Institutional Registry of Rare DiseasesNCT06573723 · Not reported · Hospital Italiano de Buenos Aires · starts Jul 1, 2024
- An Exploratory Clinical Trial of VGN-R08b in Patients With Type II Gaucher DiseaseNCT06272149 · Early Phase 1 · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · starts Mar 1, 2023
- A Study of the Safety and Preliminary Efficacy of LY-M001 Injection in the Treatment of Adult Patients With Gaucher…NCT06162338 · Not applicable · He Huang · starts Nov 15, 2023
- PD Frontline (Part of RAPSODI GD) Remote Assessment of People With Parkinson'sNCT06151002 · Not reported · University College, London · starts Feb 15, 2020
- GammaGA: Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal…NCT05992532 · Not reported · Fundación Española de Hematología y Hemoterapía · starts May 30, 2023
Approved 5
- Taliglucerase alfaGlucocerebroside hydrolytic enzyme
- Velaglucerase alfaGlucocerebroside hydrolytic enzyme
- EliglustatCeramide glucosyltransferase inhibitor
- ImigluceraseGlucocerebroside hydrolytic enzyme
- MiglustatCeramide glucosyltransferase inhibitor
Phase 3 2
- VenglustatCeramide glucosyltransferase inhibitor
- Vitamin e
Phase 2 6
- AfegostatBeta-glucocerebrosidase stabiliser
- Ambroxol
- BusulfanDNA inhibitor
- CyclophosphamideDNA inhibitor
- AcetylcysteineGlutathione precursor
- Arimoclomol
Phase 1 or earlier 2
- SirolimusFK506-binding protein 1A inhibitor
- PrednisoneGlucocorticoid receptor agonist
How its trials ended
158 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 37 whose ending is known, 57% met their primary endpoint, 3% missed it and 41% stopped early.
- Completed, result not reported6340%
- Ongoing4126%
- Met its primary endpoint2113%
- Status unknown1711%
- Stopped: other or unclear117%
- Stopped: enrollment or feasibility21%
- Stopped: sponsor or business decision21%
- Missed its primary endpoint11%
| Aug 10, 2026 | Phase 3, open-label, long term extension basket study of venglustat in adult and pediatric patients with Gaucher type 3 disease and adult patients with Fabry…Venglustat (GZ/SAR402671) | Sanofi-Aventis Canada Inc | Pending |
| Dec 23, 2025 | A phase 3 safety and efficacy trial of FLT201 gene therapy in patients with Gaucher disease type 1FLT201 | Spur Therapeutics Limited | Ongoing |
| Feb 14, 2022 | A phase 3, multicenter, multinational, randomized, doubleblind, double-dummy, active-comparator study to evaluate the efficacy and safety of venglustat in…Venglustat (SAR402671) / Imiglucerase | Sanofi-Aventis Canada Inc | Ongoing |
| Dec 15, 2020 | A three-part study to evaluate the efficacy and safety of venglustat in combination with cerezyme in adult and pediatric patients with Gaucher disease type 3…Venglustat (SAR402671) | Sanofi-Aventis Canada Inc | Pending |
| Sep 28, 2018 | An adaptive, open-label, multinational phase 1/2 study of the safety and efficacy of ex vivo, lentiviral vector-mediated gene therapy AVR-RD-02 for subjects…AVR-RD-02 | AVROBIO | Ongoing |
| Oct 2, 2017 | Open label, two cohort (with and without imiglucerase), multicenter study to evaluate pharmacokinetics (PK), safety, and efficacy of eliglustat in pediatric…Cerdelga (eliglustat) | Sanofi | Closed |
| Jun 9, 2015 | Open label interventional multicenter phase 3b study to evaluate skeletal response to eliglustat in adult patients who successfully completed the phase 2 or…Cerdelga (eliglustat) | Sanofi | Closed |
| Jan 12, 2026 | CerezymeTreatment of non-central nervous system (CNS) manifestations of Type 1 or Type 3 Gaucher disease in adults and pediatric patients | Genzyme Corporation | Approved |
| Aug 19, 2014 | CerdelgaLong-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers… | Genzyme Corporation | Approved |
| May 1, 2012 | ELELYSO for injectionUse as long-term enzyme replacement therapy in patients with Type 1 Gaucher disease | Pfizer, Inc. | Approved |
| Feb 26, 2010 | VprivTreatment of Type I Gaucher Disease | Takeda Development Center Americas, Inc. | Approved |
| Jul 31, 2003 | ZavescaTreatment of mild to moderate Type I Gaucher disease in adults for whom enzyme replacement therapy is not a therapeutic option (e.g., due… | IC-MedTech Corporation | Approved |
| Apr 5, 1991 | CeredaseLong-term enzyme replacement therapy for children, adolescents and adult patients with a confirmed diagnosis of Type I Gaucher disease who… | Genzyme Corporation | Approved |
| Aug 24, 2026 | AmbroxolTreatment of Gaucher disease | LILA Holding AG | Designated |
| Apr 10, 2026 | Selective glucosylceramide synthase (GCS) inhibitorTreatment of Gaucher disease | Yuhan Corporation | Designated |
| Jan 13, 2026 | Adeno-associated viral vector delivering human GBA1 geneTreatment of Gaucher disease | Shanghai Vitalgen BioPharma Co., Ltd. | Designated |
| Jun 10, 2025 | AmbroxolTreatment of Gaucher disease | Kalevala Therapeutics Inc. | Designated |
| Apr 16, 2025 | AmbroxolTreatment of Gaucher disease (GD) | Agyany Pharma LTD. | Designated |
| Sep 9, 2024 | Adeno-associated virus 9 vector expressing a functional…Treatment of Gaucher Disease | National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH) | Designated |
| Oct 5, 2023 | Recombinant adeno-associated virus (rAAV)Treatment of Gaucher disease | Lingyi Biotech Co. Ltd. | Designated |
| Sep 2, 2021 | Eliglustat TartrateTreatment of Gaucher Disease Type 1 patients who are CYP2D6 ultra-rapid metabolizers and patients whose CYP2D6 genotype cannot be… | Amneal Pharmaceuticals LLC | Designated |
| Aug 11, 2021 | Recombinant adeno-associated viral vector serotype S3…Treatment of Gaucher Disease | Spur Therapeutics Limited | Designated |
| Feb 18, 2019 | Miglustat DipharmaMiglustat · generic | Dipharma Arzneimittel GmbH | EMA ↗ |
| Nov 9, 2017 | Veanibek (previously Miglustat Gen.Orph)Miglustat · generic | Gen.Orph | EMA ↗ |
| Mar 22, 2017 | YargesaMiglustat · generic | Piramal Critical Care B.V. | EMA ↗ |
| Jan 19, 2015 | CerdelgaEliglustat · orphan | Sanofi B.V. | EMA ↗ |
| Aug 26, 2010 | VprivVelaglucerase alfa | Takeda Pharmaceuticals International AG Ireland Branch | EMA ↗ |
| Nov 20, 2002 | ZavescaMiglustat | Advanz Pharma Limited | EMA ↗ |
| Nov 17, 1997 | CerezymeImiglucerase | Sanofi B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA